Article

Demethylation and upregulation of an oncogene post hypomethylating treatment

2020-07-26

Abstract excerpt

<h4>Background</h4> While hypomethylating agents (HMA) are currently used to treat myelodysplastic syndrome (MDS) patients, their effects on reactivation and/or upregulation of oncogenes are generally not well elucidated. SALL4 is a known oncogene that plays an important role in MDS. In this study, we examined the relationship between SALL4 methylation and expression, and evaluated changes of SALL4 expression and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3aa48304-2e7a-5a35-a558-c36b0298544c
DOI: 10.1101/2020.07.21.20157776

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Demethylation and upregulation of an oncogene post hypomethylating treatmentDOI 10.1101/2020.07.21.20157776Read

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.Semantic proximity Read

Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndromeSemantic proximity Read

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related diseaseSemantic proximity Read

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?Semantic proximity Read

The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.Semantic proximity Read

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity Read

Optimizing hypomethylating agents in myelodysplastic syndromesSemantic proximity Read

The DNA methylation landscape of hematological malignancies: an updateSemantic proximity Read

Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidineSemantic proximity Read

Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance.Semantic proximity Read